Is VEGF Trap-Eye Effective in Treating Macular Edema?

December 21, 2010

On Monday, Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Monday announced that their VEGF Trap-Eye drug met key treatment goals in a late-stage study on macular edema patients. The study focused on patients with macular edema because of central retinal vein occlusion.

Specifically, 56.1% of patients in the study receiving monthly injections reported improvement in vision (as compared to 12% in the control group).

Read the full story here on Bloomberg.




Jump down to form below to submit your own comments

Comments are closed.